FrancophonIA/ELRC3.0 huggingface dataset:
English: Additional adverse experiences reported regardless of causal relationship to medication that occurred more frequently in patients treated with sitagliptin (not reaching the 5 % level, but occurring with an incidence of > 0.5 % higher with sitagliptin than that in the control group) included osteoarthritis and pain in extremity.
Croatian: Dodatne nuspojave prijavljene bez obzira na uzročno-posljedičnu povezanost s liječenjem koje su se pojavile češće u bolesnika liječenih sitagliptinom (nisu dostigle razinu od 5%, ali su se pojavljivale s incidencijom > 0,5% višom sa sitagliptinom od one koju je imala kontrolna skupina) uključivale su osteoartritis i bol u ekstremitetima.
English: Adverse reactions are listed below (Table 1) by system organ class and frequency.
Croatian: Nuspojave navedene ispod (Tablica 1) su razvrstane po klasifikaciji organskih sustava i učestalosti.
English: Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway.
Croatian: Sitagliptin se primarno eliminira neizmijenjen mokraćom, a tek manji dio se metabolizira.
English: The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Croatian: Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom (RMP-a), koji se nalazi u Modulu 1.8.2
English: The clinical relevance of hOAT-3 in sitagliptin transport has not been established.
Croatian: Dosad nije utvrđen klinički značaj hOAT-3 u transportu sitagliptina.
English: Animal data do not suggest an effect of treatment with sitagliptin on male and female fertility.
Croatian: Podaci iz istraživanja na životinjama ne pokazuju da liječenje sitagliptinom ima učinak na plodnost mužjaka ni ženki.
English: Some adverse reactions were observed more frequently in studies of combination use of sitagliptin with other anti-diabetic medicinal products than in studies of sitagliptin monotherapy.
Croatian: Neke nuspojave su primijećene češće u ispitivanjima kombinirane primjene sitagliptina s drugim lijekovima za liječenje dijabetesa nego u ispitivanjima monoterapije sitagliptinom.
English: Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza oznake "EXP".
English: Sitagliptin 100 mg once daily (N= 193) Sitagliptin 100 mg once daily (N= 229)
Croatian: Ispitivanja monoterapije sitagliptin 100 mg jedanput na dan (n=193) sitagliptin 100 mg jedanput na dan (n=229)
English: Ristaben should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Croatian: Ristaben se ne smije primjenjivati u bolesnika s dijabetesom tipa 1 ili za liječenje dijabetičke ketoacidoze.
English: Digoxin: Sitagliptin had a small effect on plasma digoxin concentrations.
Croatian: Digoksin: Sitagliptin je imao malen učinak na koncentracije digoksina u plazmi.
English: Since co-administration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics, Ristaben may be administered with or without food.
Croatian: Budući da istodobno uzimanje sitagliptina s punomasnim obrokom nema učinka na farmakokinetiku, Ristaben se može uzimati s hranom ili bez nje.
English: Plasma AUC of sitagliptin increased in a dose-proportional manner.
Croatian: AUC sitagliptina u plazmi povećava se proporcionalno dozi.
English: as triple oral therapy in combination with
Croatian: kao trojna peroralna terapija, u kombinaciji
English: In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic cationic transporter (OCT).
Croatian: U kliničkim ispitivanjima sitagliptin nije značajno promijenio farmakokinetiku metformina, gliburida, simvastatina, roziglitazona, varfarina ili oralnih kontraceptiva, pružajući in vivo dokaz o niskoj sklonosti za uzrokovanje interakcija sa supstratima CYP3A4, CYP2C8, CYP2C9 i organskog kationskog transportera (OCT).
English: In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas metformin alone increased active and total GLP-1 concentrations to similar extents.
Croatian: U dvodnevnom ispitivanju u zdravih ispitanika, sitagliptin primijenjen samostalno povisio je koncentracije aktivnog GLP-1, dok je metformin primijenjen samostalno povisio koncentracije aktivnog i ukupnog GLP-1 do sličnih vrijednosti.
English: When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP.
Croatian: Kad je koncentracija glukoze u krvi normalna ili povišena, GLP-1 i GIP povećavaju sintezu inzulina i njegovo otpuštanje iz beta stanica gušterače putem unutarstaničnih signalnih puteva koji uključuju ciklički AMP.
English: Reproductive toxicity studies showed a slight treatment-related increased incidence of foetal rib malformations (absent, hypoplastic and wavy ribs) in the offspring of rats at systemic exposure levels more than 29 times the human exposure levels.
Croatian: Istraživanja reproduktivne toksičnosti ukazala su na neznatno veću incidenciju prenatalnih malformacija rebara povezanih s liječenjem (nedostatak, nerazvijenost i valovita rebra) u mladunčadi štakora pri sistemskoj izloženosti 29 puta većoj od razina izloženosti u ljudi.
English: Sitagliptin prevents the hydrolysis of incretin hormones by DPP-4, thereby increasing plasma concentrations of the active forms of GLP-1 and GIP.
Croatian: Sitagliptin sprečava hidrolizu inkretinskih hormona putem DPP-4, čime povećava koncentraciju aktivnih oblika GLP-1 i GIP-a u plazmi.
English: Co-administration of sitagliptin and metformin had an additive effect on active GLP-1 concentrations.
Croatian: Istodobna primjena sitagliptina i metformina imala je dodani učinak na koncentracije aktivnog GLP-1.
English: Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of Ristaben and periodically thereafter.
Croatian: S obzirom da se doza prilagođava temeljem bubrežne funkcije, preporučuje se procijeniti bubrežnu funkciju prije uvođenja lijeka Ristaben te periodično nakon toga.
English: Hypoglycaemia when used in combination with other anti-hyperglycaemic medicinal products In clinical trials of Ristaben as monotherapy and as part of combination therapy with medicinal products not known to cause hypoglycaemia (i.e. metformin and/or a PPAR agonist), rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.
Croatian: Hipoglikemija pri uzimanju u kombinaciji s drugim antihiperglikemijskim lijekovima U kliničkim ispitivanjima lijeka Ristaben kao monoterapije ili kao dio kombinirane terapije s lijekovima za koje nije poznato da uzrokuju hipoglikemiju (tj. metforminom i/ili agonistom PPAR), stope prijavljenih hipoglikemija u bolesnika koji su uzimali sitagliptin bile su podjednake onoj u bolesnika koji su uzimali placebo.
English: It is not known if sitagliptin is dialysable by peritoneal dialysis.
Croatian: Nije poznato može li se sitagliptin ukloniti peritonealnom dijalizom.
English: Post-marketing reports of serious hypersensitivity reactions in patients treated with sitagliptin have been reported.
Croatian: Nakon stavljanja lijeka u promet prijavljene su ozbiljne reakcije preosjetljivosti u bolesnika liječenih sitagliptinom.
English: In a clinical study sitagliptin had a small effect on plasma digoxin concentrations indicating that sitagliptin may be a mild inhibitor of p-glycoprotein.
Croatian: U jednom je kliničkom ispitivanju sitagliptin imao malen učinak na koncentracije digoksina u plazmi, što ukazuje da bi sitagliptin mogao biti blagi inhibitor p-glikoproteina.
English: In vitro transport studies showed that sitagliptin is a substrate for p-glycoprotein and organic anion transporter-3 (OAT3).
Croatian: Istraživanja transporta in vitro pokazala su da je sitagliptin supstrat p-glikoproteina i organskog anionskog transportera-3 (OAT3).
English: Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations.
Croatian: Sitagliptin je potentan i visoko selektivan inhibitor enzima DPP-4 te pri terapijskim koncentracijama ne inhibira njemu vrlo srodne enzime DPP-8 ili DPP-9.
English: The incidence of hypoglycaemia was not significantly different between the treatment groups (sitagliptin, 1.3 %; metformin, 1.9 %).
Croatian: Incidencija hipoglikemije nije se značajno razlikovala između liječenih skupina (sitagliptin 1,3%, metformin 1,9%).
English: Approximately 79 % of sitagliptin is excreted unchanged in the urine.
Croatian: Približno se 79% sitagliptina u neizmijenjenom obliku izluči mokraćom.
English: Method of administration Ristaben can be taken with or without food.
Croatian: Način primjene Ristaben se može uzimati s hranom ili bez nje.
English: The activity of GLP-1 and GIP is limited by the DPP-4 enzyme, which rapidly hydrolyzes the incretin hormones to produce inactive products.
Croatian: Aktivnost GLP-1 i GIP-a ograničava enzim DPP-4 koji brzo hidrolizira inkretinske hormone u neaktivne oblike.
English: Treatment may be administered without regard to the timing of dialysis.
Croatian: Lijek se može primijeniti neovisno o vremenu dijalize.
English: There was also a significant difference between groups with respect to change from baseline body weight (sitagliptin -0.6 kg; glipizide +1.2 kg).
Croatian: Postojala je i značajna razlika između skupina što se tiče promjene početne tjelesne težine (sitagliptin -0,6 kg, glipizid +1,2 kg).
English: This medicine can be used alone or in combination with certain other medicines (insulin, metformin, sulphonylureas, or glitazones) that lower blood sugar, which you may already be taking for your diabetes together with a food and exercise plan.
Croatian: Ovaj lijek se može uzimati sam ili u kombinaciji s nekim drugim lijekovima (inzulinom, metforminom, sulfonilurejama ili glitazonima) koji snižavaju šećer u krvi, koje, uz dijetu i tjelovježbu, možda već uzimate za liječenje šećerne bolesti.
English: The incidence of hypoglycaemia was similar across treatment groups.
Croatian: Incidencija hipoglikemije bila je slična u svim liječenim skupinama.
English: However, dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.
Croatian: Međutim, prijavljene su omaglica i omamljenost, što može utjecati na sposobnost upravljanja vozilima ili rada sa strojevima.
English: HbA1c results in placebo-controlled monotherapy and combination therapy studies*
Croatian: Tablica 2. Rezultati HbA1c u placebom kontroliranim ispitivanjima monoterapije i kombinirane terapije*
English: The incidence of hypoglycaemia in the sitagliptin group (4.9 %) was significantly lower than that in the glipizide group (32.0 %).
Croatian: Incidencija hipoglikemije u skupini na sitagliptinu (4,9%) bila je značajno niža od one u skupini na glipizidu (32,0%).
English: However, because sitagliptin is primarily renally eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin.
Croatian: Međutim, budući da se sitagliptin primarno eliminira putem bubrega, ne očekuje se da će teško oštećenje funkcije jetre utjecati na farmakokinetiku sitagliptina.
English: Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Croatian: Učestalost nepoznata: tegobe s bubrezima (ponekad zahtijevaju dijalizu), povraćanje, bol u zglobovima, bol u mišićima, bol u leđima, intersticijska bolest pluća, bulozni pemfigoid (vrsta mjehurića na koži)
English: At Week 24, the increase in daily insulin dose was 19 IU/day in patients treated with sitagliptin and 24 IU/day in patients treated with placebo.
Croatian: U 24. tjednu porast dnevne doze inzulina iznosio je 19 IU/dan u bolesnika liječenih sitagliptinom, a 24 IU na dan u bolesnika koji su primali placebo.
English: When used in combination with metformin and/or a PPAR agonist, the dose of metformin and/or PPAR agonist should be maintained, and Ristaben administered concomitantly.
Croatian: Kada se uzima u kombinaciji s metforminom i/ili agonistom PPAR, mora se zadržati ista doza metformina i/ili agonista PPAR, uz istodobnu primjenu lijeka Ristaben.
English: Sitagliptin may be a mild inhibitor of p-glycoprotein in vivo.
Croatian: Sitagliptin može biti blagi inhibitor p-glikoproteina in vivo.
English: During controlled clinical trials in healthy subjects, single doses of up to 800 mg sitagliptin were administered.
Croatian: U kontroliranim kliničkim ispitivanjima zdravim ispitanicima davane su jednokratne doze do najviše 800 mg sitagliptina.
English: In patients with normal renal function, metabolism, including via CYP3A4, plays only a small role in the clearance of sitagliptin.
Croatian: U bolesnika s normalnom funkcijom bubrega metabolizam, uključujući onaj putem CYP3A4, igra tek manju ulogu u klirensu sitagliptina.
English: This study involved 423 patients with chronic renal impairment (estimated glomerular filtration rate < 50 ml/min).
Croatian: U to su ispitivanje uključena 423 bolesnika s kroničnim oštećenjem funkcije bubrega (procijenjena brzina glomerularne filtracije < 50 ml/min).
English: In vitro data suggest that sitagliptin does not inhibit nor induce CYP450 isoenzymes.
Croatian: Podaci iz in vitro istraživanja ukazuju na to da sitagliptin ne inhibira niti inducira izoenzime CYP450.
English: Following administration of 0.25 mg digoxin concomitantly with 100 mg of sitagliptin daily for 10 days, the plasma AUC of digoxin was increased on average by 11 %, and the plasma Cmax on average by 18 %.
Croatian: Nakon istodobne primjene digoksina u dozi od 0,25 mg sa sitagliptinom u dozi od 100 mg na dan, tijekom 10 dana, AUC digoksina u plazmi porastao je za prosječno 11%, a Cmax u plazmi za prosječno 18%.
English: Effects of sitagliptin on other medicinal products
Croatian: Učinci sitagliptina na druge lijekove
English: It is not known if this medicine passes into breast milk.
Croatian: Nije poznato izlučuje li se ovaj lijek u majčino mlijeko.
English: Incidence rate per patientyears* N (%)
Croatian: Stopa incidencije na 100 bolesnikgodina* N (%)
English: However, ciclosporin, a p-glycoprotein inhibitor, did not reduce the renal clearance of sitagliptin.
Croatian: Međutim, ciklosporin, inhibitor p-glikoproteina, nije smanjio bubrežni klirens sitagliptina.
English: For adult patients with type 2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:
Croatian: U odraslih bolesnika s dijabetesom mellitus tipa 2, Ristaben je indiciran za poboljšanje regulacije glikemije:
English: The effects of GLP-1 and GIP are glucose-dependent such that when blood glucose concentrations are low, stimulation of insulin release and suppression of glucagon secretion by GLP-1 are not observed.
Croatian: Učinci GLP-1 i GIP-a su ovisni o glukozi, tako da se pri niskim koncentracijama glukoze u krvi ne opaža stimulacija otpuštanja inzulina niti supresija lučenja glukagona putem GLP-1.
English: Ciclosporin: A study was conducted to assess the effect of ciclosporin, a potent inhibitor of p-glycoprotein, on the pharmacokinetics of sitagliptin.
Croatian: Ciklosporin: Provedeno je ispitivanje procjene učinka ciklosporina, potentnog inhibitora p-glikoproteina, na farmakokinetiku sitagliptina.
English: In patients taking pre-mixed insulin, the mean daily dose was 70.9 U/day.
Croatian: U bolesnika koji su uzimali predmiješani inzulin srednja vrijednost dnevne doze bila je 70,9 U/dan.
English: The reduction in HbA1c from mean baseline values of 7.2 % was -0.43 % for sitagliptin and -0.57 % for metformin (Per Protocol Analysis).
Croatian: Sniženje HbA1c u odnosu na srednje početne vrijednosti od 7,2% iznosilo je -0,43% za sitagliptin i -0,57% za metformin (analiza po realiziranom planu ispitivanja, engl. per protocol analysis).
English: The incidence of hypoglycaemia in the sitagliptin group (6.2 %) was significantly lower than that in the glipizide group (17.0 %).
Croatian: Incidencija hipoglikemije u skupini na sitagliptinu (6,2%) bila je značajno niža nego u skupini na glipizidu (17,0%).
English: 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets 50 x 1 film-coated tablets
Croatian: 14 filmom obloženih tableta 28 filmom obloženih tableta 30 filmom obloženih tableta 56 filmom obloženih tableta 84 filmom obloženih tableta 90 filmom obloženih tableta 98 filmom obloženih tableta 50 x 1 filmom obložena tableta
English: However, more patients in the sitagliptin group discontinued due to lack of efficacy than in the glipizide group.
Croatian: Međutim, zbog manjka djelotvornosti liječenje je prekinulo više bolesnika u skupini na sitagliptinu nego u onoj na glipizidu.
English: In rats, there was an increased incidence of hepatic adenomas and carcinomas at systemic exposure levels 58 times the human exposure level.
Croatian: U štakora je opažena povećana incidencija adenoma i karcinoma jetre pri sistemskoj izloženosti 58 puta većoj od razina izloženosti u ljudi.
English: The mean glipizide dose used in the comparator group was 10 mg per day with approximately 40 % of patients requiring a glipizide dose of  5 mg/day throughout the study.
Croatian: Srednja vrijednost doze glipizida u usporednoj skupini bila je 10 mg na dan, a približno 40% bolesnika trebalo je dozu od ≤ 5 mg/dan glipizida tijekom cijelog ispitivanja.
English: In patients with type 2 diabetes with hyperglycaemia, these changes in insulin and glucagon levels lead to lower haemoglobin A1c (HbA1c) and lower fasting and postprandial glucose concentrations.
Croatian: U bolesnika s dijabetesom tipa 2 s hiperglikemijom, ove promjene u razinama inzulina i glukagona dovode do sniženja hemoglobina A1c (HbA1c) te nižih koncentracija glukoze u krvi natašte i poslije obroka.
English: Human data are lacking.
Croatian: Nema podataka u ljudi.
English: Transient treatment-related physical signs, some of which suggest neural toxicity, such as open-mouth breathing, salivation, white foamy emesis, ataxia, trembling, decreased activity, and/or hunched posture were observed in dogs at exposure levels approximately
Croatian: Prolazni fizički znakovi povezani s liječenjem, od kojih neki upućuju na neurotoksičnost, poput disanja otvorenih usta, salivacije, povraćanja bijele pjene, ataksije, drhtanja, smanjene aktivnosti i/ili pogrbljenog držanja tijela, opaženi su kod pasa pri razinama izloženosti otprilike 23 puta većima od razina kliničke izloženosti.
English: In Phase I multiple-dose studies, there were no dose-related clinical adverse reactions observed with sitagliptin with doses of up to 600 mg per day for periods of up to 10 days and 400 mg per day for periods of up to 28 days.
Croatian: U ispitivanjima višekratnih doza faze I nisu zamijećene o dozi ovisne klinički značajne nuspojave sitagliptina s dozama do najviše 600 mg na dan tijekom perioda do 10 dana, odnosno u dozi od 400 mg na dan tijekom perioda do 28 dana.
English: The glucose-dependent mechanism of sitagliptin is distinct from the mechanism of sulphonylureas, which increase insulin secretion even when glucose levels are low and can lead to hypoglycaemia in patients with type 2 diabetes and in normal subjects.
Croatian: Mehanizam djelovanja sitagliptina ovisan je o glukozi i razlikuje se od mehanizma djelovanja sulfonilureja, koje pojačavaju lučenje inzulina čak i kada su razine glukoze u krvi niske i mogu dovesti do hipoglikemije u bolesnika s dijabetesom tipa 2 i u normalnih ispitanika.
English: The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin-treated patients and 0.2 % in placebo-treated patients.
Croatian: Incidencija neovisno potvrđenih događaja pankreatitisa iznosila je 0,3% u bolesnika liječenih sitagliptinom i 0,2% u onih koji su primali placebo.
English: The incidence of hypoglycaemia was not significantly different between the treatment groups (sitagliptin, 6.3 %; glipizide, 10.8 %).
Croatian: Incidencija hipoglikemije nije se značajno razlikovala između liječenih skupina (sitagliptin 6,3%, glipizid 10,8%).
English: In addition, after 12 weeks, the mean reductions in HbA1c (sitagliptin -0.59 %; placebo -0.18 %) and FPG (sitagliptin -25.5 mg/dL; placebo -3.0 mg/dL) were generally similar to those observed in other monotherapy studies in patients with normal renal function (see section 5.2).
Croatian: Osim toga, nakon 12 tjedana je srednja vrijednost sniženja HbA1c (sitagliptin -0,59%, placebo -0,18%) i glukoze u krvi natašte (sitagliptin -25,5 mg/dl, placebo -3,0 mg/dl) općenito bila slična onoj opaženoj u ostalim ispitivanjima monoterapije u bolesnika s normalnom funkcijom bubrega (vidjeti dio 5.2).
English: Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
Croatian: Ristaben je također indiciran kao dodatak inzulinu (sa ili bez metformina) kada dijeta i tjelovježba uz stabilnu dozu inzulina ne omogućuju odgovarajuću regulaciju glikemije.
English: Animal studies have shown excretion of sitagliptin in breast milk.
Croatian: Istraživanja na životinjama pokazala su da se sitagliptin izlučuje u mlijeko životinja.
English: In another study involving 91 patients with type 2 diabetes and chronic renal impairment (creatinine clearance < 50 ml/min), the safety and tolerability of treatment with sitagliptin at 25 or 50 mg once daily were generally similar to placebo.
Croatian: U drugom ispitivanju u koje je uključen 91 bolesnik s dijabetesom tipa 2 i kroničnim oštećenjem funkcije bubrega (klirens kreatinina < 50 ml/min), sigurnost i podnošljivost liječenja sitagliptinom u dozi od 25 ili 50 mg jedanput na dan općenito su bile slične placebu.
English: Hospitalization for unstable angina
Croatian: Hospitalizacija zbog nestabilne angine Smrt zbog bilo kojeg uzroka
English: The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 litres.
Croatian: Srednji volumen distribucije sitagliptina u stanju dinamičke ravnoteže nakon primjene jednokratne intravenske doze od 100 mg u zdravih ispitanika je približno 198 litara.
English: There have been post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors including sitagliptin.
Croatian: Nakon stavljanja lijeka u promet prijavljen je bulozni pemfigoid u bolesnika koji uzimaju inhibitore DPP-4, uključujući sitagliptin.
English: In patients taking non-pre-mixed (intermediate/long-acting) insulin, the mean daily dose was 44.3 U/day.
Croatian: U bolesnika koji su primali nemiješani inzulin (srednjedugog/dugog djelovanja) srednja vrijednost dnevne doze bila je 44,3 U/dan.
English: Ristaben contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.
Croatian: Ristaben sadrži djelatnu tvar sitagliptin, koja pripada skupini lijekova koji se zovu DPP-4 inhibitori (inhibitori dipeptidil-peptidaze 4), koji snižavaju razine šećera u krvi u odraslih bolesnika sa šećernom bolešću tipa 2.
English: Body weight decreased from baseline in both groups (sitagliptin, -0.6 kg; metformin -1.9 kg).
Croatian: Tjelesna težina se u obje skupine smanjila u odnosu na početne vrijednosti (sitagliptin -0,6 kg, metformin -1,9 kg).